arrow
J

Jason K. Yano

Takeda Pharmaceutical Company Ltd
H指数:25
被引数:4,923

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Structure-based design of a novel series of cholesterol 24-hydroxylase (CH24H) inhibitors bearing 1,3-oxazole as a heme–iron binding group

基于结构的1,3-噁唑作为血红素-铁结合基团的新型胆固醇24-羟化酶(CH24H)抑制剂系列的设计

2025-06-110
OA
Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors
2024-07-300
OAAI
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

在RAS驱动的癌症中通过RMC-6236抑制RAS-GTP的翻译和治疗评估

2024-04-0931
OAAI
Synthesis and biological evaluation of novel selective androgen receptor modulators (SARM-s) Part Ill: Discovery of 4-(5-oxopyrrolidine-1-yl) benzonitrile derivative 2f as a clinical candidate

新型选择性雄激素受体调节剂 (SARM-s) 的合成和生物学评价第iii部分: 发现4-(5-氧代吡咯烷-1-基) 苄腈衍生物2f作为临床候选物

2017-07-0137
PREAI
Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
2013-08-01106
PREAI
Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives
2012-09-0119
PRE
Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds
2012-03-1473
PREAI
Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold
2011-11-04206
PREAI
Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554 (vol 19, pg 4482, 2011)
2011-09-010
OAAI
Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: A new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554
2011-08-0145
PRE
Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554

发现靶向Lys554的有效,选择性和口服生物利用度的基于喹啉的二肽基肽酶IV抑制剂

2011-08-0136
PRE
Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
2011-02-2242
PREAI